Larimar Therapeutics, Inc.
LRMR
$4.36
-$0.19-4.18%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -2.42% | -0.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.89% | -0.34% | |||
| Operating Income | 10.89% | 0.34% | |||
| Income Before Tax | 10.58% | -1.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 10.58% | -1.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 10.58% | -1.59% | |||
| EBIT | 10.89% | 0.34% | |||
| EBITDA | 10.92% | 0.37% | |||
| EPS Basic | 10.68% | -1.35% | |||
| Normalized Basic EPS | 10.66% | -1.35% | |||
| EPS Diluted | 10.68% | -1.35% | |||
| Normalized Diluted EPS | 10.66% | -1.35% | |||
| Average Basic Shares Outstanding | 0.10% | 0.24% | |||
| Average Diluted Shares Outstanding | 0.10% | 0.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||